ProMIS Neurosciences强调血浆pTau作为早期预测因素在PRECISE-AD试验中，出版物在2026年第二季度中期读数之前加强了生物标志物驱动的设计

Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS' PRECISE-AD trial

ProMIS on track to leverage new plasma pTau insights with planned Q2 2026 interim readout

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced a publication in the peer-reviewed journal Alzheimer's & Dementia: Translational Research & Clinical Interventions. entitled, "Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease."